| Literature DB >> 36175976 |
Sigma Hossain1, Minhaj Rahim Choudhury2, Md Mahmudul Haque3, Surayea Yeasmin2, Farzana Hossain4, Mohammad Mostafa Zaman5.
Abstract
OBJECTIVE: To assess the relationship between functional disability and health-related quality of life (HRQoL) among systemic sclerosis (SSc) patients.Entities:
Keywords: Functional disability; Health Assessment Questionnaire-Disability Index (HAQ-DI); Health-related quality of life; Short Form 36 (SF-36); Systemic sclerosis
Year: 2022 PMID: 36175976 PMCID: PMC9524111 DOI: 10.1186/s41927-022-00291-x
Source DB: PubMed Journal: BMC Rheumatol ISSN: 2520-1026
Fig. 1Flow diagram illustrating recruitment of study subject based on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Guidelines for cross-sectional studies. * HAQ-DI—Health Assessment Questionnaire-Disability Index, HRQoL—Health-related quality of life, SF-36—Short Form-36
Demographic, clinical, and laboratory features of the systemic sclerosis (SSc) patients
| Variables | All SSc patients | Diffuse cutaneous systemic sclerosis | Limited cutaneous systemic sclerosis | |
|---|---|---|---|---|
| (n = 78) | (n = 60) | (n = 18) | ||
| Age, mean (standard deviation) years | 36.5 (11.3) | 36.8 (10.3) | 35.3 (14.3) | 0.69a |
| Female | 71 (91.0) | 56 (93.3) | 15 (83.3) | 0.34b |
| Skin manifestations | ||||
| Sclerodactyly | 66 (84.6) | 54 (90.0) | 12 (66.7) | 0.03b |
| Pinch nose | 61 (78.2) | 51 (85.0) | 10 (55.5) | 0.02b |
| Calcinosis | 47 (60.3) | 42 (70.0) | 5 (27.8) | 0.00c |
| Vascular manifestations | ||||
| Raynaud’s Phenomenon | 70 (89.7) | 57 (95.0) | 13 (72.2) | 0.02b |
| Pitting scars of fingertips | 53 (67.9) | 42 (70.0) | 11 (61.1) | 0.567c |
| Musculoskeletal manifestations | ||||
| Arthritis/arthralgia | 37 (47.4) | 28 (46.7) | 9 (50.0) | 0.99c |
| Can’t close fist properly | 32 (41.0) | 25 (41.7) | 7 (38.9) | 0.99c |
| Muscle weakness | 32 (41.0) | 26 (43.3) | 6 (33.3) | 0.59c |
| Flexion contracture | 16 (20.5) | 10 (16.7) | 6 (33.3) | 0.18b |
| Gastrointestinal manifestations | ||||
| Microstomia | 61 (78.2) | 52 (86.7) | 9 (50.0) | 0.00b |
| Gastro-oesophageal reflux | 47 (60.3) | 39 (65.0) | 8 (44.4) | 0.17c |
| Modified Rodnan skin score, Median (Interquartile range) | 19.0 (10.0–32.0] | 20.0 (15.0–34.0) | 10.0 (6.0–21.0) | 0.02d |
| Antibody | (n = 63) | (n = 48) | (n = 15) | |
| Antinuclear antibody | 37 (58.7) | 26 (43.3) | 11 (64.7) | 0.17c |
| Anti-topoisomerase antibody | 24 (38.1) | 20 (33.3) | 4 (22.2) | 0.41c |
| Anti-centromere antibody | 2 (3.2) | 2 (3.3) | 0 (0.0) | 0.99b |
| Echocardiography findings | (n = 24) | (n = 16) | (n = 8) | |
| Valvulopathy (Tricuspid regurgitation) | 24 (48.0) | 16 (27.1) | 8 (44.4) | 0.17c |
| Pulmonary artery systolic pressure | ||||
| Normal (12–15 mmHg) | 24 (48.0) | 21 (55.3) | 3 (25.0) | 0.07c |
| Increased ((≥ 25 mmHg) | 26 (52.0) | 17 (44.7) | 9 (75.0) | |
| High resolution CT scan | (n = 17) | (n = 9) | (n = 8) | |
| Ground glass pattern | 10 (58.8) | 5 (8.3) | 5 (27.8) | 0.05b |
| Fibrosis | 7 (41.2) | 4 (6.7) | 3 (16.7) | 0.34b |
a = Student’s t-test, b = Fisher’s Exact test, c = Chi-square test, d = Mann–Whitney U test
Outcome measure scores (HAQ-DI and SF-36) of patients with systemic sclerosis, median [interquartile range]
| Scores | All SSc patient (n = 78) | Diffuse cutaneous systemic sclerosis (n = 60) | Limited cutaneous systemic sclerosis (n = 18) | ||
|---|---|---|---|---|---|
| HAQ-DI scores | |||||
| Dressing | 1.0 [0.0–2.0] | 1.0 [0.0–1.7] | 1.0 [0.0–2.0] | 0.40a | |
| Rising | 1.0 [0.0–1.2] | 1.0 [0.0–2.0] | 1.0 [0.0–1.0] | 0.16a | |
| Eating | 1.0 [0.0–3.0] | 1.0 [0.0–3.0] | 1.0 [0.0–2.2] | 0.25a | |
| Walking | 1.5 [1.0–2.0] | 2.0 [1.0–2.0] | 1.0 [0.0–2.0] | 0.49a | |
| Hygiene | 2.0 [0.0–3.0] | 2.0 [0.0–3.0] | 1.5 [0.0–3.0] | 0.91a | |
| Reach | 1.0 [0.0–3.0] | 1.0 [0.2–3.0] | 1.0 [0.0–2.0] | 0.28a | |
| Grip | 1.0 [0.0–3.0] | 1.0 [0.0–3.0] | 2.0 [0.0–3.0] | 0.50a | |
| Activity | 2.0 [1.0–3.0] | 2.0 [1.0–3.0] | 2.0 [0.0–3.0] | 0.97a | |
| Total HAQ-DI | 1.4 [0.6–2.1] | 1.3 [0.5–2.1] | 1.4 [0.7–2.0] | 0.70a | |
| Disability index, n (%) | |||||
| Mild | 29 (37.2) | 22 (36.7) | 7 (38.9) | ||
| Moderate | 26 (33.3) | 19 (31.7) | 7 (38.9) | 0.72b | |
| Severe | 23 (29.5) | 19 (31.7) | 4 (22.2) | ||
| SF-36 scores | |||||
| Physical functioning | 20.0 [10.0–55.0] | 20.0 [10.0–48.7] | 15.0 [8.7–66.2] | 0.99a | |
| Role physical | 0.0 [0.0–100.0] | 0.0 [0.0–100.0] | 0.0 [0.0–81.2] | 0.65a | |
| Role emotional | 0.0 [0.0–100.0] | 0.0 [0.0–100.0] | 33.0 [0.0–100.0] | 0.76a | |
| Energy/Fatigue | 20.0 [10.0–40.0] | 17.5 [10.0–35.0] | 25.0 [18.7–46.2] | 0.08a | |
| Emotional wellbeing | 40.0 [20.0–61.0] | 40.0 [17.0–60.0] | 48.0 [34.0–46.2] | 0.17a | |
| Social functioning | 50.0 [25.0–75.0] | 50.0 [25.0–75.0] | 56.2 [34.4–78.1] | 0.62a | |
| Pain | 45.0 [22.5–67.5] | 45.0 [23.1–67.5] | 45.0 [22.5–80.0] | 0.88a | |
| General health | 20.0 [8.7–45.0] | 15.0 [5.0–38.7] | 30.0 [23.7–61.2] | 0.01a | |
| Physical component summary | 26.2 [15.0–58. 1] | 26.2 [15.3–53.1] | 31.6 [14.4–60.9] | 0.59a | |
| Mental component summary | 42.0 [19.6–60.6] | 37.0 [17.1–59.7] | 48.1 [23.3–64.8] | 0.28a | |
a = Mann–Whitney U test, b = Chi-square test,
HAQ-DI: Health Assessment Questionnaire-Disability Index, SF-36: Short Form-36
Spearman correlation coefficient of domains of SF-36 (Short Form-36) with HAQ-DI (Health Assessment Questionnaire-Disability Index)
| SF-36 domains | Spearman correlation with HAQ-DI | |
|---|---|---|
| Physical functioning | − 0.644 | < 0.00 |
| Role physical | − 0.449 | < 0.00 |
| Role emotional | − 0.202 | 0.08 |
| Energy / Fatigue | − 0.351 | 0.00 |
| Emotional wellbeing | − 0.366 | 0.00 |
| Social functioning | − 0.273 | 0.02 |
| Pain | − 0.493 | < 0.00 |
| General health | − 0.342 | 0.00 |
| Physical component summary | − 0.629 | < 0.00 |
| Mental component summary | − 0.344 | 0.00 |
Comparison of HAQ-DI score and SF-36 scores among SSc patients with different disease duration (in years), median [interquartile range]
| Early | Intermediate | Late | ||
|---|---|---|---|---|
| DcSSc patients | ||||
| HAQ-DI scores | 1.2 [1.1–1.9] | 0.8 [0.4–2.2] | 1.7 [0.7–2.1] | 0.448a |
| SF-36 scores | ||||
| Physical component summary | 40.0 [20.4–55.6] | 34.1 [15.0–63.7] | 21.9 [15.0–38.1] | 0.138a |
| Mental component summary | 50.2 [20.0–69.9] | 44.3 [17.2–66.3] | 28.4 [15.7–57.2] | 0.202a |
| LcSSc patients | ||||
| HAQ-DI scores | 1.3 [0.3–1.9] | 1.9 [0.2–2.1] | 1.5 [0.8–1.9] | 0.957a |
| SF-36 scores | ||||
| Physical component summary | 24.1 [12.5–64.8] | 25.0 [14.4–60.6] | 58.1 [24.7–66.6] | 0.704a |
| Mental component summary | 55.4 [24.2–78.2] | 33.6 [27.3–61.2] | 47.4 [15.0–64.9] | 0.884a |
For DcSSc, early (< 3 years), intermediate (3–6 years) and late (> 6 years), for LcSSc, early (< 5 years), intermediate (5–10 years) and late (> 10 years)
aMann-Whitney U test,
HAQ-DI: Health Assessment Questionnaire Disability Index; SF-36: Short Form-36, DcSSc: diffuse cutaneous systemic sclerosis, LcSSc: limited cutaneous systemic sclerosis,
Physical component summary and mental component summary of SF-36 and HAQ-DI of the patients according to clinical manifestations (n = 78), median [interquartile range]
| Clinical manifestations | Physical component summary | Mental component summary | HAQ-DI |
|---|---|---|---|
| Sclerodactyly | 24.0 [15.0–54.4]* | 33.4 [17.6–61.0] | 1.5 [0.7–2.1] |
| 47.2 [36.2–71.2] | 48.5 [35.6–55.9] | 1.0 [0.4–1.4] | |
| Calcinosis | 21.9 [13.7–53.1]* | 23.7 [12.7–57.2]** | 1.7 [0.7–2.2] * |
| 38.7 [21.3–60.9] | 51.8 [32.8–70.3] | 1.2 [0.5–1.5] | |
| Incomplete fist closure | 21.9 [13.9–39.1]* | 32.6 [17.6–58.9] | 2.0 [1.5–2.2]** |
| 38.7 [16.2–63.3] | 46.4 [20.5–70.3] | 0.9 [0.3–1.6] | |
| Raynaud’s Phenomenon | 25.0 [15.0–53.1]* | 37.0 [18.6–60.6] | 1.4 [0.7–2.1] * |
| 65.3 [21.1–73.7] | 51.3 [21.0–77.3] | 0.6 [0.2–1.6] | |
| Pitting scar | 23.7 [15.0–55.6] | 33.2 [16.7–60.6] | 1.4 [0.7–2.1] |
| 39.4 [18.1–59.1] | 45.6 [21.9–60.7] | 1.2 [0.3–1.8] | |
| Arthralgia/arthritis | 21.9 [12.5–43.1]** | 33.2 [17.1–51.7] | 1.6 [1.1–2.2] * |
| 39.4 [20.4–64.4] | 50.4 [20.3–70.4] | 1.1 [0.4–2.1] | |
| Muscle weakness | 21.2 [13.3–37.0]** | 33.0 [15.8–62.4] | 2.0 [1.1–2.2]** |
| 38.7 [21.2–63.3] | 47.8 [21.9–60.6] | 1.2 [0.4–1.8] | |
| Flexion contracture | 17.9 [9.7–23.3]** | 28.9 [15.8–60.3] | 2.1 [1.5–2.2]** |
| 37.2 [17.6–60.0] | 45.5 [20.5–63.1] | 1.2 [0.4–2.1] | |
| Gastro-oesophageal reflux | 23.1 [15.0–50.6] | 44.2 [18.0–61.9] | 1.5 [0.7–2.1] |
| 31.2 [21.2–65.0] | 39.9 [20.7–60.5] | 1.2 [0.4–1.9] | |
| Microstomia | 25.0 [15.6–55.6] | 44.2 [21.9–60.0] | 1.4 [0.6–2.1] |
| 38.1 [11.9–64.4] | 32.7 [16.1–70.4] | 1.0 [0.3–1.9] | |
| Pulmonary arterial hypertension | 21.8 [13.7–42.8] | 28.8 [21.6–57.2] | 1.4 [0.2–2.1] |
| 27.8 [15.3–60.0] | 48.7 [13.7–66.3] | 1.2 [0.6–1.9] | |
| Female sex | 25.0 [15.0–53.1] * | 33.6 [18.0–59.5] | 1.5 [0.7–2.1] * |
All P values reached from Mann–Whitney test, *P < 0.05, **P < 0.01, SF-36 indicates Short Form-36; HAQ-DI: Health Assessment Questionnaire-Disability Index
Predictors for impaired health-related quality of life measured by physical component summary (PCS) and mental component summary (MCS) of SF-36 and functional disability measured by HAQ-DI among systemic sclerosis patients
| Variables | Standardized beta coefficients for | ||
|---|---|---|---|
| PCS | MCS | HAQ-DI | |
| Age (in years) | − 0.149 | − 0.127 | 0.282* |
| Sex (men = 1, women = 2) | − 0.164 | − 0.117 | 0.246* |
| Sclerodactyly (no = 1, yes = 2) | − 0.013 | – | – |
| Calcinosis (no = 1, yes = 2) | − 0.053 | − 0.287* | 0.038 |
| Incomplete fist closure (no = 1, yes = 2) | − 0.080 | – | 0.324* |
| Raynaud’s Phenomenon (no = 1, yes = 2) | − 0.256* | – | – |
| Arthralgia/arthritis (no = 1, yes = 2) | − 0.195 | – | 0.068 |
| Muscle weakness (no = 1, yes = 2) | − 0.120 | – | 0.165 |
| Flexion contracture (no = 1, yes = 2) | − 0.257* | – | 0.191 |
*P < 0.05
R square for model 1 (PCS): 0.351, R square for model 2 (MCS): 0.129, R square for model 3 (HAQ-DI): 0.458
SF-36 indicates Short Form-36; HAQ-DI: Health Assessment Questionnaire-Disability Index